Home > others & > Benserazide HCl

Benserazide HCl

盐酸苄丝肼,盐酸卞丝肼,Ro-4-4602

Benserazide hydrochloride是芳香族L-氨基酸脱羧酶（AAAD）和DOPA脱羧酶抑制剂。

目录号
EY1532
EY1532
EY1532
纯度
99.18%
99.18%
99.18%
规格
50 mg
100 mg
500 mg
原价
120
200
300
售价
120
200
300
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Benserazide HCl is a peripherally-acting aromatic L-amino acid decarboxylase (AAAD) or DOPA decarboxylase inhibitor.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Dalila Mango et. Al. Experimental Neurology, 261, 733-743 (2014).
    [2] Jacob Wienecke et. Al. Journal of Neuroscience, 34(36), 11984-12000 (2014).
    [3] Elena Dragicevic et. Al. Brain, 137(Pt 8), 2287-2302 (2014).

    分子式
    C10H16ClN3O5    		 分子量
    293.7    		 CAS号
    14919-77-8    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    58 mg/mL    		 Water
    58 mg/mL    		 Ethanol
    1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT02741947 Parkinson Disease Drug: Levodopa Benserazide Madopar|Drug: Levodopa Benserazide Teva Italia IRCCS San Raffaele|Agenzia Italiana del Farmaco Phase 4 2014-04-01 2016-04-14
    NCT01327261 Healthy Volunteers Drug: Levodopa + benserazide University of Buenos Aires|Laboratorios Phoenix S.A.I.C.y F. Phase 4 2009-08-01 2011-08-03
    NCT02778594 Parkinson's Disease (PD) Drug: BIA 3-202|Drug: Placebo|Drug: levodopa 100 mg / benserazide 25 mg Bial - Portela C S.A. Phase 1 2005-09-01 2016-06-13
    NCT00144209 Restless Legs Syndrome Drug: pramipexole|Drug: levodopa in combination with benserazide Boehringer Ingelheim Phase 3 2003-02-01 2013-10-31
    NCT02169466 Parkinson's Disease (PD) Drug: BIA 9-1067|Drug: Placebo|Drug: MadoparHBS Bial - Portela C S.A. Phase 1 2009-01-01 2015-10-02
    NCT02169895 Parkinson's Disease (PD) Drug: BIA 9-1067|Drug: Placebo|Drug: Prolopa Bial - Portela C S.A. Phase 1 2008-09-01 2015-01-08
    NCT02763852 Parkinson's Disease Drug: BIA 3-202|Drug: Placebo|Drug: Madopar125 Bial - Portela C S.A. Phase 1 2001-04-01 2016-05-04
    NCT02769793 Parkinson Disease Drug: Levodopa dispersible|Drug: Levodopa Seoul National University Hospital|SMG-SNU Boramae Medical Center|Samsung Medical Center Phase 4 2015-06-01 2017-02-21
    NCT01533116 Parkinson Disease Drug: BIA 9-1067|Drug: Placebo|Drug: levodopa/carbidopa|Drug: levodopa/benserazide Bial - Portela C S.A. Phase 1 2009-03-01 2015-10-14
    NCT02169414 Parkinson's Disease (PD) Drug: BIA 9-1067 5 mg|Drug: BIA 9-1067 25 mg|Drug: levodopa/carbidopa 100/25|Drug: Placebo|Drug: levodopa/benserazide 100/25 mg Bial - Portela C S.A. Phase 1 2010-02-01 2015-11-19
    NCT00941265 Aphasia Drug: levodopa and benserazide|Drug: placebo University Hospital, Geneva 2007-02-01 2014-12-02
    NCT03091543 Parkinson Disease Drug: Madopar HBS 125|Drug: Placebo|Drug: BIA 6-512 25 mg dose|Drug: BIA 6-512 50 mg dose|Drug: BIA 6-512 100 mg dose|Drug: BIA 6-512 200 mg dose Bial - Portela C S.A. Phase 1 2004-05-04 2017-03-21
    NCT01568047 Parkinson's Disease Drug: Placebo|Drug: BIA 9-1067|Drug: BIA 9-1067|Drug: BIA 9-1067|Drug: Levodopa/Carbidopa|Drug: Levodopa/Benzerazide Bial - Portela C S.A. Phase 2 2010-02-01 2015-11-23
    NCT02073773 Ischaemic Stroke Drug: Levodopa|Other: Virtual Reality based therapy Singapore General Hospital|Singapore University of Technology and Design Phase 3 2014-01-01 2017-02-08
    NCT02680977 Parkinson's Disease Other: MP-Equivalent|Other: MP-Low|Other: MP+DDCI|Drug: LD+DDCI|Drug: LD-DDCI|Other: Placebo ASST Gaetano Pini-CTO|Fondazione Grigioni per il Morbo di Parkinson Phase 2 2016-02-01 2016-10-04
    NCT00203164 Parkinson's Disease Drug: rasagiline mesylate Teva Pharmaceutical Industries Phase 3 2002-05-01 2010-03-08
    NCT01568034 Parkinson's Disease Drug: BIA 9-1067|Drug: BIA 9-1067|Drug: BIA 9-1067|Drug: Placebo|Drug: Levodopa/Carbidopa|Drug: Levodopa/Benzerazide Bial - Portela C S.A. Phase 2 2009-04-01 2014-12-19
    NCT01968031 Idiopathic Parkinson's Disease Drug: Istradefylline 40 mg|Drug: Istradefylline 20 mg|Drug: Placebo Kyowa Hakko Kirin Pharma, Inc.|Kyowa Hakko Kirin Co., Ltd|Kyowa Kirin Pharmaceutical Development, Inc. Phase 3 2013-10-01 2016-12-09
    NCT02610231 Idiopathic Parkinson's Disease Drug: Istradefylline 20 mg or 40 mg Kyowa Hakko Kirin Pharma, Inc.|Kyowa Hakko Kirin Co., Ltd|Kyowa Kirin Pharmaceutical Development, Inc. Phase 3 2015-12-01 2017-03-13
    NCT00812760 Retinal Diseases Drug: levodopa Medical University of Vienna Phase 4 2001-10-01 2008-12-19
    NCT01227655 Parkinson's Disease Drug: BIA 9-1067|Drug: Placebo|Drug: Levodopa|Drug: Carbidopa|Drug: Benserazide Bial - Portela C S.A. Phase 3 2011-03-01 2015-09-21
    NCT01568073 Parkinson's Disease Drug: BIA 9-1067|Drug: Entacapone|Drug: Placebo|Drug: Levodopa|Drug: Carbidopa|Drug: Benserazide Bial - Portela C S.A. Phase 3 2011-03-01 2015-09-01
    NCT01646255 Idiopathic Parkinson's Disease Drug: Rotigotine|Drug: Placebo Patch|Drug: L-dopa UCB Pharma|UCB Trading (Shanghai) Co. Ltd. Phase 3 2012-07-01 2016-01-29

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：